Johnson & Johnson announced results from a subgroup analysis of the Phase 3 CARTITUDE-4 study. The data show CARVYKTI significantly improved progression-free survival, or PFS, compared to standard therapies of pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone for patients with lenalidomide-refractory multiple myeloma after one prior line of therapy, including patients with functional high-risk multiple myeloma. FHR was defined as progressive disease within 18 months after receiving autologous stem cell transplant or the start of initial frontline therapy in patients with no ASCT. These data were featured as an oral presentation at the 2024 American Society of Clinical Oncology, or ASCO, Annual Meeting and will also be shared at the 2024 European Hematology Association, or EHA, Congress, the company noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson completes Shockwave acquisition, sees EPS dilution
- Vanda Pharma completes transfer of FDA Marketing Authorization for Ponvory
- PayPal upgraded, UiPath downgraded: Wall Street’s top analyst calls
- Johnson & Johnson reinstated with a Neutral at Goldman Sachs
- Sarepta to replace ShockWave Medical in S&P 400 at open on 6/3